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1 Abstract
Genetic markers can be used as instrumental variables, in an analogous way to ran-
domization in a clinical trial, to estimate the causal relationship between a pheno-
type and an outcome variable. Our purpose is to extend existing methods for such
Mendelian randomization studies to the context of multiple genetic markers measured
in multiple studies, based on analysis of individual participant data. First, for a sin-
gle genetic marker in one study, we show that the usual ratio of coefficients approach
can be reformulated as a regression with heterogeneous error in the explanatory vari-
able. This can be implemented using a Bayesian approach, which is next extended
to include multiple genetic markers. We then propose a hierarchical model for under-
taking a meta-analysis of multiple studies, in which it is not necessary that the same
genetic markers are measured in each study. This provides an overall estimate of the
causal relationship between the phenotype and the outcome, and an assessment of its
heterogeneity across studies. As an example, we estimate the causal relationship of
blood concentrations of C-reactive protein on fibrinogen levels using data from eleven
studies. These methods provide a flexible framework for efficient estimation of causal
relationships derived from multiple studies. Issues discussed include weak instrument
bias, analysis of binary outcome data such as disease risk, missing genetic data, and
the use of haplotypes.
Keywords: Mendelian randomization; instrumental variables; causal association;
meta-analysis; Bayesian methods
2 Introduction
In traditional observational epidemiological studies, associations between a risk factor
or phenotype (X) and outcome (Y) are often biased by unmeasured confounders or re-
verse causation. Mendelian randomization [1] is a technique for using genetic markers
(G) as instrumental variables (IV) to assess the true causal association without direct
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experiment. It uses the random allocation of genes at conception in an analogous
way to treatment assignment in a randomized control trial [2]. By finding genetic
markers associated with levels of the phenotype, the different genotypes give rise to
groups which, under certain assumptions, are randomly assigned and so independent
of measured and unmeasured confounders (U) and the effects of reverse causation.
The assumptions underlying an IV analysis are depicted in the directed acyclic graph
(DAG) in Figure 1. An IV is a variable G which is [3]:
a) independent of any possible confounders (ie. G ⊥ U),
b) associated with the phenotype (ie. G ¬ ⊥ X), and
c) independent of the outcome given the phenotype and confounders (ie.G ⊥ Y |X,U).
There are many ways in which these assumptions may be violated [4], some of which








Figure 1: Directed acyclic graph (DAG) of Mendelian randomization assumptions
We consider the case where the outcome Y is continuous, and defer the issues
relating to binary outcomes to the discussion. If the phenotype X and all confounders
U are exactly measured, the causal association between X and Y (β1 in Figure 1) can
be estimated using standard multiple regression of Y on X and U. In a study where
G, X and Y are measured, but some confounders U are not, several IV-based methods
are available to estimate the causal association between X and Y. The most basic,
the ratio of coefficients method [5, 3], can be used when there is one instrument, for
example a single nucleotide polymorphism (SNP), providing genetic information: ei-
ther the SNP is dichotomized (for example by combining the heterozygous group with
one of the homozygous groups; recessive or dominant model), or linearity is assumed
according to the number of variant alleles (additive model). In the latter case, the
causal association is estimated as the ratio of the regression coefficient of the outcome
Y on the number of variant alleles of the SNP to the regression coefficient of the
phenotype X on the number of variant alleles of the SNP [4]. As the regression coef-
ficients are asymptotically normal, approximate confidence intervals for the ratio can
be calculated using Fieller’s theorem [6] or the asymptotic variance can be estimated
using a Taylor expansion [7]; the correlation between the two regression coefficients
can be estimated by bootstrapping, but is often assumed to be zero since it is typically
small [8].
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The two-stage least squares (2SLS) method [4] can be used for multiple, polychoto-
mous SNPs in one study. Least squares regression of the phenotype on the SNPs is
used to obtain fitted values for the phenotype (Xˆ|G). Each SNP can be considered
either as a continuous variable (per allele analysis) or as a factor with three levels
(2df analysis). The effects of different SNPs can be combined additively; alternatively
interactions can be included. The regression coefficient of the outcome Y on these
fitted values for the phenotype is the estimate of the causal association. The point
estimate from the 2SLS method performed per allele is equal to that from the ratio
of coefficients method in the case of a linear effect of a single IV. If the uncertainty
in the fitted values is ignored in the second stage regression, the standard error of
the estimate of the causal association will be underestimated, and so a correction is
needed [9]. To define confidence limits, the asymptotic normal distribution of the
2SLS estimator is used.
Methods based on genetic IVs are now being extensively used in practice. For ex-
ample, they have been used for estimating the causal relationship between blood con-
centrations of C-reactive protein (CRP) and insulin resistance [10], CRP and carotid
intima-media thickness [11], and folate levels and coronary heart disease [8]. A recur-
ring problem is that the anticipated causal effects are only of moderate size, and the
effects of genetic markers on the phenotype are typically small, so that IV techniques
suffer from low power and poor precision. Typically sample sizes of tens of thousands
are required [12, 13]. Meta-analysis of results from different studies is therefore often
necessary, but current meta-analysis methods are restricted to studies all measuring
the same single dichotomous or trichotomous SNP [8, 14].
We seek here to extend these established methods: firstly to gain power by using
evidence from multiple studies, secondly to synthesize evidence across studies which
use different SNPs as instrumental variables, thirdly to use multiple SNPs simulta-
neously [15], and finally to avoid the problems of “weak instruments” [16]. IV-based
estimates using a weak instrument, where the association between phenotype and the
IV is not statistically strong, suffer bias in the direction of the original observational
association and deviation from an asymptotic normal to a more heavy-tailed distri-
bution [17]. The F-statistic from the regression of phenotype on SNPs is commonly
used as a measure of instrument strength [18].
We first describe a Bayesian approach to the estimation of causal effects using
individual data on genetic characteristics. We present the simple case of a single
genetic marker in one study (Section 3), and extend this to an analysis of multiple
genetic markers in one study (Section 4). A hierarchical model for meta-analysis is
then developed (Section 5) which efficiently deals with different genetic markers mea-
sured in different studies, and with heterogeneity between studies. The focus in this
paper is on data from representative cross-sectional population studies; application to
case-control studies is deferred to the discussion (Section 6).
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3 A single genetic marker in one study
3.1 Conventional methods
We first consider the case of a single SNP in one study, where confounding causes the
observational estimate of the association of phenotype and outcome to be different
from the causal relationship. Let individual i have phenotype level xi, outcome yi,
genotype gi taking a value in {0,1,2}, and unmeasured confounder ui. We assume
that all the confounders can be summarized by a single value ui. Similarly to Palmer
et al. [19], we consider the model represented in Figure 1:
xi = α0 + α1gi + α2ui + ²xi (1)
yi = β0 + β1xi + β2ui + ²yi
with ui ∼ N (0, σ2u), ²xi ∼ N (0, σ21), ²yi ∼ N (0, σ22) independently. As an example,
we simulate data for a sample of size 300, containing 12 individuals with gi = 2, 96
with gi = 1 and 192 with gi = 0, corresponding to Hardy-Weinberg equilibrium for a







(0, 1, 0, 2, -3, 1, 0.25, 0.25), and consider the cases of a weak instrument (α1 = 0.3,
giving an expected F-value for the regression of X on G of 7), a moderate instrument
(α1 = 0.5, F-value 20) and a strong instrument (α1 = 1, F-value 75). Figure 2 shows
the simulated data grouped by genotype graphically.
The observational estimates obtained by regressing Y on X (Table 1) are far
from the true causal association (β1 = 2) as expected because of the strong nega-
tive confounding (U is positively related to X but negatively to Y). The IV-based
ratio method (assuming zero correlation between coefficients) gives estimates com-
patible with β1 = 2, but with a wide confidence interval in the case of the weak or
moderate instrument.
3.2 A Bayesian method
Estimating the causal parameter by the ratio method is equivalent to determining the
gradients in Figure 2 [4]. We can reformulate the problem as one of linear regression
with heterogeneous error in X. For each genotype value j = 0, 1, 2 we calculate the
mean level of the phenotype x¯j with its variance σ
2
xj and mean outcome y¯j with its
variance σ2yj. The model is:
x¯j ∼ N (ξj, σ2xj) (2)
y¯j ∼ N (ηj, σ2yj)
ηj = β0 + β1 ξj
Thus we assume that each observed mean phenotype x¯j is from a normal distribution
with unknown true mean ξj and known variance σ
2
xj, each observed mean outcome y¯j




















































Figure 2: Graphs of mean outcome (y¯) against mean phenotype (x¯) in three ge-
netic groups for the weak, moderate and strong instrument simulated examples of
Section 3.1. Error bars are 95% CIs for the means.
there is a linear relationship between η and ξ. β1 represents the increase in outcome
for unit increase in true phenotype and is the parameter of interest.
To implement this model, we employ Bayesian analysis and Markov Chain Monte
Carlo (MCMC) methods with Gibbs sampling. This allows extension to more compli-
cated situations, as in the next sections. We used vague priors (independent normals
with zero mean and large variance of 1002) for the regression parameters and each
ξj. We performed this analysis in WinBUGS [20] using 150,000 iterations, discarding
the first 1000 as “burn-in”, employing different starting values to assess convergence
of the posterior distribution and sensitivity analyses to show lack of dependence on
the prior distributions. The posterior distributions shown in Figure 3 are non-normal,
with a heavier tail towards larger values especially for the weaker instruments. For
this reason, the posterior median of the distribution of β1 is taken as the estimate
of the causal association. Table 1 shows that the estimates and intervals from this
Bayesian group-based method are similar to those from the ratio method. Other sim-
ulated examples (not shown) also demonstrated similar results. The 2SLS per allele
method gives the same estimates as the ratio method, but the intervals are symmetric
and so deviate from the ratio and Bayesian methods for the weaker instruments.
This Bayesian method assumes that the variances σ2xj and σ
2
yj are known, whereas
in fact they need to be estimated from the data, an issue which is addressed in the
next section.
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Weak instrument - (F=7) Estimate 95% CI/CrI
Observational estimate -0.358 -0.506, -0.210
Ratio method 1.637 0.563, 6.582
Bayesian method 1.496 0.536, 7.190
2SLS method 1.637 -0.126, 3.400
Moderate instrument - (F=20) Estimate 95% CI/CrI
Observational estimate -0.251 -0.393, -0.109
Ratio method 2.555 1.481, 6.007
Bayesian method 2.417 1.473, 4.592
2SLS method 2.555 0.801, 4.309
Strong instrument - (F=75) Estimate 95% CI/CrI
Observational estimate 0.108 -0.061, 0.276
Ratio method 2.136 1.632, 2.906
Bayesian method 2.107 1.633, 2.817
2SLS method 2.136 1.469, 2.804
Table 1: Causal parameter estimates and confidence/credible intervals using ratio,
2SLS and Bayesian methods compared with observational estimate for the weak, mod-
erate and strong instrument simulated examples of Section 3.1
4 Multiple genetic markers in one study
4.1 Methods
If we have data in the study from more than one SNP then, provided they satisfy the
IV assumptions above, all SNPs can be used simultaneously to divide the population
into many subgroups. For each diallelic SNP, there are three genotypic categories,
corresponding to 0, 1 or 2 variant alleles. For a dataset with n diallelic SNPs, we have
a maximum 3n categories, for each of which we can measure the mean phenotype
and outcome, and examine the regression as in (2) above to estimate β1, the causal
association. In practice, fewer than the maximum number of genotypic groups will be
observed, due to correlation between SNPs caused by linkage disequilibrium (LD).
If the number of groups is large, and so their sizes nj are small, then the assumption
of exact knowledge of σ2xj and σ
2
yj for each group is not appropriate. Indeed if nj = 1,
the group-specific variance cannot even be calculated. It is then preferable to base
the analysis on the standard deviation in the whole population for the phenotype (σx)
and the outcome (σy), using an individual-based model for phenotype and outcome.
For each individual i in category j, we have:
xij ∼ N (ξj, σ2x) (3)
yij ∼ N (ηj, σ2y)
ηj = β0 + β1 ξj
The observed phenotype and outcome for each individual are here modelled using
normal distributions, although other distributions might be more appropriate for some
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Figure 3: Kernel-smoothed density of posterior distribution of the causal parameter
for the weak, moderate and strong instrument simulated examples of Section 3.1 using
the Bayesian method of Section 3.2
applications. The information about ξj now depends on the population standard
deviation for the phenotype as well as the size of the group. In the application below,
vague Uniform[0,20] priors are used for σx and σy, while the other priors remain as
before.
An alternative analysis is to assume a linear relationship between the phenotype
and the number of variant alleles for each SNP which is also additive across SNPs. If
this structure is appropriate, the analysis should be more efficient as the correlation
between similar genotypes is accounted for and fewer parameters are estimated. Then
we use these modelled values in the second stage regression. Writing G as the matrix
of genotypes, so that Gik is the number of variant alleles in SNP k for individual i,
and αk as the first stage regression coefficients, then the model is:




xi ∼ N (ξi, σ2x)
yi ∼ N (ηi, σ2y)
ηi = β0 + β1 ξi
Independent vague N (0, 1002) priors are now placed on the αk rather than the ξi.
The values of αk depend, through feedback, on all the data including the outcome Y.
Models (3) and (4) are the equivalent of 2SLS in a Bayesian setting, except that
there is feedback on the first stage coefficients from the second stage regression; the
posterior distribution of the causal association parameter β1 naturally incorporates
the uncertainty in the first stage regression, but with no assumption of asymptotic
normality on its distribution.
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4.2 Application to C-reactive protein and fibrinogen
C-reactive protein (CRP) is an acute-phase protein produced by the liver as part of the
inflammation response pathway. Fibrinogen is a soluble blood plasma glycoprotein,
which enables blood-clotting and is also associated with inflammation. The pathway
of inflammation is not well understood, but is important as both CRP and fibrinogen
are proposed as risk markers of coronary heart disease (CHD) [13]. Furthermore,
although CRP is associated with CHD risk, this association reduces on adjustment for
various risk factors, and attenuates to near null on adjustment for fibrinogen [21]. It is
important therefore to assess whether CRP causally affects levels of fibrinogen, since
if so adjusting for fibrinogen would represent an overadjustment. The CRP gene has
several common variations which are associated with different blood concentrations
of CRP. We use IV techniques to estimate the causal effect of CRP on fibrinogen. As
CRP has a positively skewed distribution, we take its natural logarithm, and assume
a linear relationship between fibrinogen and loge(CRP). All SNPs used here as IVs
are in the CRP regulatory gene on chromosome 1.
The Cardiovascular Health Study [22] is an observational study of risk factors for
cardiovascular disease in adults 65 years or older. We use cross-sectional baseline data
for 4469 white subjects from this study, in which four diallelic SNPs relevant to CRP
were measured: rs1205, rs1800947, rs1417938 and rs2808630. Each of these SNPs
was found to be associated with CRP levels. We checked their associations with
seven known CHD risk factors (age, body mass index, triglycerides, systolic blood
pressure, total cholesterol, low and high density lipoproteins) for each SNP, and found
no significant associations (P < 0.05) out of the 28 examined. This suggests that the
SNPs are valid instruments.
We used each of the techniques for estimating causal association mentioned above.
The ratio method for each SNP separately is based on per allele regressions. For the
2SLS method, we use first a per allele model additive across SNPs and secondly a
fully factorial version of the 2df model where each observed genotype is placed in a
separate category. The 2SLS per allele model is equivalent to the structure-based
Bayesian model (4) and the 2SLS factorial model is equivalent to the individual-
based Bayesian model (3). When using the group-based regression (2), we excluded
all genotypic groups with less than 5 subjects (14 subjects excluded, Figure 4). The
individual-based (3), structure-based (4), ratio and 2SLS analyses include all subjects.
A sensitivity analysis was performed excluding from the 2SLS factorial and Bayesian
individual-based analyses all individuals from genotypic groups with less than 5 sub-
jects. The observational increase in fibrinogen (µmol/l) per unit increase in log(CRP)
is 0.937 (s.e. 0.024) and correlation between fibrinogen and log(CRP) is 0.501. The
F4,4464 statistic in the regression of log(CRP) on the SNPs additively per allele is 27.2,
indicating that the instruments together are moderately strong, with a relative size
bias less than 5% [16, 23]. As we have used more IVs than we have phenotypes, we
can perform an overidentification test. The Sargan test [24] is a test of the validity
of the IV and linearity assumptions in the model. The test statistic is 7.15, which
compared to a χ23 distribution gives a p-value of 0.067, meaning that the validity of
the instruments is not rejected at the 5% level.
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The ratio method gives a different point estimate for each SNP, all of which are
compatible with zero association (Table 2). Using the 2SLS methods on all of the
SNPs together, we obtain answers which synthesize all of the relevant data for each
of the SNPs. The Bayesian methods give causal estimates consistent with the 2SLS
estimates (Table 2). The Bayesian structural-based and 2SLS per allele models give
lower estimates of causal association than the other models, with 95% CIs that in-
clude zero. The Bayesian credibility intervals are (appropriately) asymmetric, as no
normal assumption has been made. The Bayesian structural-based and 2SLS per al-
lele models give lower estimates of causal association than the other models. The
Bayesian individual-based and the 2SLS factorial methods both give different results
when individuals from small genotypic groups are excluded. This is due to weak in-
struments leading to a bias in the causal estimate in the direction of the confounded
(observational) association [16]. We return to bias from weak instruments in the
discussion.
Method Estimate 95% CI
Ratio using rs1205 0.234 -0.169 to 0.660
Ratio using rs1417938 -0.608 -1.581 to 0.137
Ratio using rs1800947 0.203 -0.478 to 0.940
Ratio using rs2808630 2.722 −∞ to ∞
2SLS factorial using all SNPs 0.376 0.088 to 0.665
2SLS factorial (excluding small groups) 0.280 -0.041 to 0.601
2SLS per allele using all SNPs 0.200 -0.138 to 0.538
Bayesian methods Estimate 95% CrI
Group-based (excluding small groups) 0.342 0.004 to 0.698
Individual-based 0.389 0.049 to 0.728
Individual (excluding small groups) 0.300 -0.045 to 0.666
Structural-based 0.212 -0.157 to 0.586
Table 2: Comparison of the causal estimates of increase in fibrinogen (µmol/l) per unit
increase in loge(CRP) in the Cardiovascular Health Study. 95% confidence/credible
interval (CI/CrI) are shown. Small groups are genotypic groups with less than 5
subjects.
5 Multiple genetic markers in multiple studies
5.1 Methods
The above framework leads naturally to a model for meta-analysis across multiple
studies. Assumption c) in Section 2 for IVs ensures that, in principle, the same pa-
rameter β1 is being estimated regardless of how many and which SNPs are available
in each study. This is because the outcome is independent of the IV given the phe-
notype (which is measured) and the confounders (which are averaged over). We thus
propose a hierarchical model for β1 estimated across multiple studies as follows. For
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Figure 4: Plot of mean fibrinogen against mean log(CRP) in the Cardiovascular Health
Study stratified by genotypic group. Error bars are 95% CIs. Groups with less than
5 subjects omitted. The size of the shaded squares is proportional to the number of
subjects in each group. The dashed line is the estimate of causal association from the
group-based method without random effects.
a fixed-effect meta-analysis, we assume the same value of β1 for each study. For a
random-effects meta-analysis, we allow β1m from study m to come from a distribution
with mean β1 and variance ψ
2. This acknowledges the possibility that the causal
parameters are somewhat different across studies, as is plausible due to the influences
of different population characteristics, but that they are expected to have generally
similar values.
For the group-based regression (2), for group j in study m, a fixed-effect meta-
analysis is:
x¯jm ∼ N (ξjm, σ2xjm) (5)
y¯jm ∼ N (ηjm, σ2yjm)
ηjm = β0m + β1 ξjm
Values for β0m, the constant terms in the regression, will vary depending on the average
level of outcome in the population in each study, and are thus given independent vague
N (0, 1002) priors for each study.
For a random-effect meta-analysis, the last line of (5) is replaced by:
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ηjm = β0m + β1m ξjm (6)
β1m ∼ N (β1, ψ2)
We use a Uniform[0,20] prior for ψ in the example below.
These modifications to the simple group-based analysis (2) for a meta-analysis
context can also be similarly made to the individual-based model (3), and to the
structured model (4). For example, the full model using a structured model (4),
assuming heterogeneity between studies, for individual i and SNP k = 1 . . . Km in
study m is:




xim ∼ N (ξim, σ2xm)
yim ∼ N (ηim, σ2ym)
ηim = β0m + β1m ξim
β1m ∼ N (β1, ψ2)
In this model, we assume that the first stage regression coefficients αkm are unrelated
in the different studies. An extra sophistication would be to assume that these coef-
ficients are common or related when different studies involve the same set of SNPs.
Example WinBUGS code is given in the appendix.
5.2 Application to C-reactive protein and fibrinogen
We give an example of meta-analysis of eleven studies [13] using the methods de-
scribed. In addition to the Cardiovascular Health Study (CHS) used in Section 4.2,
we incorporate data from a further eight general population cohort studies: British
Women’s Heart and Health Study (BWHHS), Copenhagen City Heart Study (CCHS),
Copenhagen General Population Study (CGPS), English Longitudinal Study of Age-
ing (ELSA), Framingham Health Study (FRAM), Northwick Park Heart Study II
(NPHS2), Rotterdam Study (ROTT), and Whitehall II Study (W2). In each of these
the analyses presented here are cross-sectional, based on baseline measurements of
CRP and fibrinogen. We also use data from two case-control studies, the Nurses’
Health Study (NHS) and Stockholm Heart Epidemiology Program (SHEEP), again
with CRP and fibrinogen measured at baseline. We use the data from controls alone
since these better represent cross-sectional population studies. Details of these studies
are summarized in Table 3.
To avoid problems with weak instruments, we want to choose genetic instruments
which together are strongly related to log(CRP). For this, the instrument was chosen
to maintain the F statistic above 10 and to include sequentially, where available,
each of SNPs rs1205, one of rs1130864 and rs1417938 (these SNPs are in complete
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LD), rs3093077, rs1800947 and rs2808630. In the meta-analysis we use between 2
and 4 SNPs as instruments in each study; the Sargan overidentification tests were
satisfied (Table 3). The choice of instruments here is not made a priori, as should
ideally be the case, but pragmatically to exemplify the method. For comparison
with the Bayesian methods, we use the study-specific 2SLS causal estimates and
corresponding asymptotic standard errors in a standard two-step inverse variance
weighted meta-analysis (using a moment estimator of the between-study variance in
the case of random-effects meta-analysis). Mean log(CRP) and fibrinogen levels for
the genotypic groups for six of the studies are shown in Figure 5.
Study genes used a Participants Excluded F value df Overid p-value
BWHHS g1, g3, g5 3188 7 16.7 (3, 3184) 0.638
CCHS g1, g2, g4 7998 5 29.6 (3, 7994) 0.358
CGPS g1, g2, g4 35679 5 152.0 (3, 35675) 0.439
CHS g1, g3, g5, g6 4469 15 27.2 (4, 4464) 0.067
ELSA g1, g2, g4 4409 8 24.7 (3, 4405) 0.367
FRAM g1, g2, g4 1575 4 10.0 (3, 1571) 0.447
NHS g1, g6 414 0 13.2 (2, 411) 0.984
NPHS2 g1, g2, g4 2153 3 11.6 (3, 2149) 0.344
ROTT g1, g2 2077 2 11.9 (2, 2074) 0.983
SHEEP g1, g2, g4 1044 4 10.5 (3, 1040) 0.680
W2 g1, g2, g4 4354 5 21.5 (3, 4350) 0.469
Total 67361 58
Table 3: Summary of studies in meta-analysis of Section 5.2: SNPs measured, number
of participants with complete genetic data, number of participants in genotypic groups
of size less than 5 excluded from some analyses, F value with degrees of freedom (df),
p-value from Sargan test of overidentification from additive per allele regression of
phenotype on SNPs used as IVs
ag1 = rs1205, g2 = rs1130864, g3 = rs1417938, g4 = rs3093077, g5 = rs1800947, g6 = rs2808630
Table 4 shows a causal association of log(CRP) on fibrinogen which does not signif-
icantly differ from the null, except for the structural-based fixed-effect meta-analysis,
which suggests a weak negative causal association. Groups of size less than 5 have
been omitted in the 2SLS factorial, group-based and individual-based analyses. There
is no clear preference for the random-effects models from the Deviance Information
Criterion (DIC) [25]. The DIC should only be used to compare between a fixed-
or random-effect model, and not between models based on different data structures.
Again, the structural-based models give lower estimates of causal association than the
other methods.
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Figure 5: Plot of mean fibrinogen against mean log(CRP) for six studies from Sec-
tion 5.2 stratified by genetic group. Error bars are 95% CIs. Groups with less than
5 subjects omitted. The size of the shaded squares is proportional to the number of
subjects in each group.
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Fixed-effect meta-analysis Estimate 95% CI/CrI DIC a
2SLS factorial -0.005 -0.139 to 0.130
2SLS per allele -0.086 -0.255 to 0.082
Group-based -0.008 -0.142 to 0.125 -242.1
Individual-based -0.036 -0.164 to 0.090 500692
Structural-based -0.136 -0.276 to -0.002 501037
Random-effects meta-analysis Estimate 95% CI/CrI DIC ψ
2SLS factorial -0.007 -0.151 to 0.137 0.072
2SLS per allele -0.086 -0.255 to 0.082 0.000
Group-based -0.017 -0.234 to 0.177 -244.5 0.188
Individual-based -0.039 -0.228 to 0.153 500692 0.155
Structural-based -0.150 -0.365 to 0.048 501037 0.169
Table 4: Estimates of increase in fibrinogen (µmol/l) per unit increase in loge(CRP),
95% confidence/credible interval (CI/CrI), deviance information criterion (DIC) and
heterogeneity parameter (ψ) in meta-analysis of eleven studies using 2SLS and
Bayesian methods. Genotypic groups with less than 5 individuals excluded from
the 2SLS factorial, group-based and individual-based analyses.
aNote: DIC should be used to compare between a fixed- or random-effect model and not between
models.
6 Discussion
In this paper, we have described a Bayesian approach to analysis of Mendelian ran-
domization studies. We introduced the approach in a simple example of a confounded
association with one IV. We extended the method to use multiple IVs, to use individ-
ual participant data and to incorporate an explicit, here additive, genetic model. We
then show how this leads naturally to a meta-analysis, which can be performed even
with heterogeneous genetic data. These methods have been applied in the estimation
of the causal association of CRP levels on fibrinogen.
6.1 Bayesian methods in IV analysis
The Bayesian approach has similarities to the 2SLS method. In both, fitted values of
phenotype are estimated for each genotypic group, which are then used in a regression
of outcome on phenotype. In 2SLS, these fitted values are assumed to be precisely
known in the second stage regression, and a correction is made to the second stage
standard error to account for this using sandwich variance estimators. In the Bayesian
framework, the fitted values of phenotype and outcome are estimated simultaneously,
and the standard error in the causal parameter is directly estimated from the MCMC
sampling process. This means that no assumption is made on the distribution of
the causal parameter, giving appropriately sized standard errors and skew CIs. The
Bayesian approach allows us to be explicit about the assumptions made. This gives
us flexibility to determine the model according to what we believe is plausible without
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being limited to linear or normal assumptions.
Additionally, the Bayesian approach provides a framework to perform analyses
that are not possible using 2SLS. These include meta-analysis in a single hierarchical
model, imputation of missing data, use of haplotypes with uncertainty, and analysis
of binary outcomes, each of which is discussed below. It also allows for more accurate
inference when using instruments which are weak.
Bayesian methods have not been widely proposed for IV analyses or applied in
Mendelian randomization studies. Although Bayesian methods for IV analysis have
been suggested in the econometrics literature [26, 27], their use is not common and
differences between the fields mean that methods cannot easily be translated into an
epidemiological setting [28]. McKeigue et al. [29] have performed a Bayesian analysis
in the single SNP and single study situation, but regarding the parameter of interest
as the “ratio of the causal effect to crude [observational] effect”. We prefer to regard
β1, the causal association, as the parameter of interest.
6.2 Meta-analysis
Methods for meta-analysis of Mendelian randomization studies have not been exten-
sively discussed, and have been restricted to studies measuring one identical SNP
[8, 30, 14]. In applications, meta-analyses of studies have concentrated on testing for
a causal effect, without accounting for the uncertainty in the estimated mean differ-
ence in phenotype values between genotypic groups [31, 32]. Where this uncertainty
has been accounted for, confidence intervals for the causal association have been too
wide to exclude a moderate causal association [33, 34]. Our proposed analysis thus
extends this previous work in a number of ways: first by using a flexible Bayesian
framework that eliminates the problems caused by non-normal causal estimates, sec-
ond by presenting a coherent framework for estimation of the causal association using
data from multiple studies, and third by allowing the use of different genetic markers
in different studies.
An advantage of the Bayesian setting for meta-analysis is that the whole analysis
can be performed in one step. This keeps each study distinct within the hierarchical
model, only combining studies at the top level. This is more effective at dealing
with heterogeneity, both statistical and in study design, than performing separate
meta-analyses on each of the genotype-phenotype and genotype-outcome associations
[8]. An alternative approach where the causal association estimate and its precision
are estimated in each study, and these estimates combined in a meta-analysis in a
second stage, is not recommended for two reasons. First, the distribution of each
causal estimate is not normal (especially if the instrument is not strong), and so
the uncertainty is not well represented by its standard error, and secondly, some
causal estimates from individual studies may have infinite variance. Examples of
these problems are apparent in Figure 3 and Table 2.
15
6.3 Weak instruments
A cause for concern in IV analysis is the bias created by using “weak instruments”,
that is instruments not strongly associated with the phenotype. When several in-
struments are used, an instrument is strong if it explains sufficient variance in the
phenotype given the other included instruments. Due to the correlation between
SNPs, an instrument which is strong on its own may not be strong when considered
in addition to other instruments. As the number of instruments increases, if no more
of the variation in the phenotype is explained, then the overall instrument becomes
weaker and two problems occur. Firstly, the theoretical bias of the IV estimator in-
creases, due to the random correlation between the IVs and unmeasured confounders
[35]. If the variation in the phenotype explained by confounders is relatively large
compared to the variation in the phenotype caused by the IVs, then the instruments
may model the variation in the confounders rather than the systematic variation from
the genetic differences. This will give rise to a correlation between the confounders
and the fitted phenotype values, which will lead to bias of the IV estimate in the
direction of the confounded estimate [17, 23]. This bias affects all the methods con-
sidered: the ratio of coefficients method, 2SLS and the proposed Bayesian method.
Secondly, as the instruments weaken, the distribution of the causal estimate becomes
heavy-tailed, leading to possible underestimation of the size of a test based on 2SLS
[23], although recent work on modifying the 2SLS method has concentrated improving
properties of test size and confidence intervals with weak instruments [36, 37]. The
Bayesian method has an advantage here, in that it makes no assumption of normality.
The shape of the posterior distribution for the causal parameter β1 reflects its true
uncertainty.
An extreme case of weak instruments is where multiple instruments place each
individual in their own separate genetic group. Then the IV estimate, derived from
the regression as in Figure 2, is equal to the observational confounded estimate. The
generally quoted advice that an instrument with F > 10 is strong is an oversimpli-
fication [17]. A modified list of values for a version of the F statistic that limit bias
and preserve test size due to Stock et al. (2005) [23] is quoted in the function ivreg2
in Stata [9].
Instruments should be specified in Mendelian randomization studies prior to data
collection. When this is not possible, instruments should be chosen so as not to use
those which give little additional strength to the G-X association. Overidentification
tests, such as the Sargan or Basmann test [9] can be performed to test the validity
of instruments. However, it should not be thought that an overidentification test is a
cure-all: instruments that pass the test can still give estimates that suffer from bias.
Sensitivity analyses, especially when the F statistic is below 10, should be performed
using different instruments and models of genetic association to informally investigate
heterogeneity of estimates indicating possible bias or violation of IV assumptions.
Although the individual-level model includes all of the participants, the inclusion of
many small groups potentially weakens the instruments in the model and so increases
bias. Small groups will not have enough participants for confounder levels to be
assumed equal between groups. The structural model may then be preferred, and will
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be less biased and more efficient if the additive assumptions for the effects of genotype
on phenotype are valid. Fewer parameters are estimated and groups with similar
genotypes will have correlated estimated true levels of phenotype, which provides
extra information in the analysis. In each of our analyses, the individual and group-
based models give more positive estimates of causal association than the structural-
based model. This is due to greater bias in the direction of the observed association
in the individual and group-based models from weaker instruments with more degrees
of freedom in the G-X association.
6.4 Missing data and haplotype assignment
If there are missing SNP data when applying the individual-based or group-based
Bayesian models, and if we can assume that this missingness is not associated with
any variable except possibly conditional on the genotype, then the pattern of missing
data satisfies the IV assumptions. For each SNP, missing values can be included as
a separate category when defining the subgroups. If there are missing genetic data
when applying the structural model, we can impute the missing data M times using
the correlation between SNPs with software such as fastPHASE [38]. These multiple
imputations can then be included in the Bayesian model, for example using the Win-
BUGS function m ∼ dpick(1,M). Alternatively, if we believe that the variation in the
phenotype is better explained by haplotypes than by genotypes, then we can use stan-
dard software to infer haplotypes [38] and instead use these haplotype assignments
in a multiple imputation, with the true phenotype level as the sum of contributions
from each haplotype [4].
6.5 Binary outcomes
The Bayesian group-level method can be applied to binary outcomes, such as disease
events, using a normal approximation to the distribution of log-odds as the outcome.
In this case, for example, y¯j and σ
2






respectively where pj is the observed probability of the event
in group j, n1j the number of events and n2j the number of non-events. Alternatively,
we can model the probability of an event directly using logistic regression. We replace
the normal distribution of the outcome in each group in model (2) with a binomial
distribution as follows:
n1j ∼ Binomial(pij, n1j + n2j) (8)
logit(pij) = β0 + β1 ξj
For an individual-level analysis of binary data, as in model (3), the outcome yij for
individual i in genotype group j takes the value of 0 or 1. Then the first line in model
(8) is replaced by yij ∼ Binomial(pij, 1). Similar adaptations for binary outcomes can
be made to the meta-analysis models (5) and (7).
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Such models for binary outcomes are valid for testing the causal hypothesis β1 = 0.
However, they do not provide unbiased estimators of a non-zero causal parameter
[2], due to the non-collapsibility of the log-odds function over the distribution of
the unknown confounders [39]. Alternative methods, including marginal structural
models [40] and structural mean models [41], have been proposed for binary outcomes
in a classical setting, but these do not provide consistent estimators either [42]. An
alternative estimator, usually called the control variable approach, involves including
the residuals from the first-stage regression of X on G into the second stage regression
of Y on Xˆ [43]. This has been shown usually to reduce bias for IV analyses involving
binary outcomes in the Mendelian randomization setting [19]. An alternative approach
would be to use a relative risk model. This does not suffer the same problems of
non-collapsibility and the parameter estimated from such an approach is the relevant
causal parameter [2]. Application of these ideas and methods within our Bayesian
model formulation needs investigation.
6.6 Conclusion
The validity of IV analyses relies on the assumptions specified in the introduction.
These assumptions can only be partially verified from data, and there are a num-
ber of ways in which they may be violated for Mendelian randomization studies [4].
Whereas the association between the genotypes and measured confounders can be
assessed, and checked that they are compatible with chance, associations with unmea-
sured confounders clearly cannot be checked. Potential correlations caused by linkage
disequilibrium between the SNPs of interest and other genetic variants, which act on
the outcome through different biological pathways, would also violate the assumptions
implicit in Figure 1. The argument against the existence of such pathways is usually
biological rather than statistical. Finally it is difficult to rule out the possibility that
a genetic mutation leads, through developmental compensation or canalization, to
feedback regulation which affects the distribution of confounders. Thus causal esti-
mates derived from all IV analyses should be subject to the caveat that they rely
on assumptions. Nevertheless, our proposed Bayesian method for meta-analysis of
Mendelian randomization studies is a useful methodological advance. It should also
find application in the context of the increasing number of consortia that are now col-
lating the relevant genetic, phenotype and outcome data from multiple studies [13].
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7 Appendix:
7.1 WinBUGS code for random-effects meta-analysis of group-
based model
model {
# prior for hierarchical causal estimate (parameter of interest)
betatrue ~ dnorm(0, 0.000001)
# prior for standard deviation of individual study estimates
betasd ~ dunif(0, 20)
betatau <- pow(betasd, -2)
for(m in 1:S) { # S = number of studies
# prior for regression intercept parameter
beta0[m] ~ dnorm(0, 0.000001)
# distribution of study-specific causal estimates
beta[m] ~ dnorm(betatrue, betatau)
for (j in 1:G[m]) { # G[m] = number of genetic subgroups in study m
# distribution of phenotype in subgroup j, study m
x[j, m] ~ dnorm(xi[j, m], xtau[j, m])
# distribution of outcome in subgroup j, study m
y[j, m] ~ dnorm(eta[j, m], ytau[j, m])
# prior for true value of phenotype in subgroup j, study m
xi[j, m] ~ dnorm(0, 0.000001)
# linear model of true outcome on true phenotype








# prior for fixed causal estimate (parameter of interest)
beta ~ dnorm(0, 0.000001)
for(m in 1:S) {
# prior for regression intercept parameter
beta0[m] ~ dnorm(0, 0.000001)
alpha0[m] ~ dnorm(0, 0.000001)
# prior for study phenotype standard deviation
xsd[m] ~ dunif(0, 20)
xtau[m] <- pow(xsd[m], -2)
# prior for study outcome standard deviation
ysd[m] ~ dunif(0, 100)
ytau[m] <- pow(ysd[m], -2)
for(k in 1:G[m]) { # G[m] = number of genes in study m
# prior for gene-phenotype regression parameters
alpha[k, m] ~ dnorm(0, 0.000001)
}
for (i in 1:N[m]) { # N[m] = number of individuals in study m
# linear model of true phenotype on genes
xi[i, m] <- inprod(alpha[1:G[m], m], gene[i, 1:G[m], m]) + alpha0[m]
# distribution of phenotype in individual i, study m
x[i, m] ~ dnorm(xi[i, m], xtau[m])
# distribution of outcome in individual i, study m
y[i, m] ~ dnorm(eta[i, m], ytau[m])
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